All In Biotech

Drug Trial Radar · NCT06722157

A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

Randomized, Double-masked, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of Two Regimens of Intravitreal BI 771716 Against Pegcetacoplan in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration VERDANT Trial

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 202 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

202

Actual

Start

Jan 6, 2025

Primary completion

Oct 26, 2026

Study completion Oct 26, 2026

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Dec 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine called BI 771716 with a medicine called pegcetacoplan. BI 771716 is being developed to treat people with geographic atrophy. Pegcetacoplan is a medicine already used to treat people with geographic atrophy. In this study, participants receive either BI 771716 or pegcetacoplan as injections in the eye. Participants are in the study for a little longer than a year and visit the study site every 4 weeks. At the visits, the study doctor checks the eyes of the participants. The results are compared between the groups of participants to see whether the treatment works. The study doctor also regularly checks participants' health and takes note of any unwanted effects.

Conditions

  • Macular Degeneration, Age-related
  • Geographic Atrophy

Interventions

  • BI 771716Drug

    BI 771716

  • PegcetacoplanDrug

    Pegcetacoplan

  • Sham comparator to BI 771716Drug

    Sham comparator to BI 771716

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Slope of change from baseline in square root transformed geographic atrophy (GA) area as measured by fundus autofluorescence (FAF) in the study eye expressed in millimeter (mm)/yearTime frame: At Baseline , at Week 56

Locations

46 sites in 1 country. Site status is shown where the registry gives one.

  • Associated Retina Consultants

    Gilbert, Arizona

  • Associated Retina Consultants, Ltd.

    Phoenix, Arizona

  • Phoenix Retina Associates

    Phoenix, Arizona

  • Retina Macula Institute of Arizona

    Scottsdale, Arizona

  • Global Research Management

    Glendale, California

  • Retina Associates of Southern California

    Huntington Beach, California

  • Retinal Consultants Medical Group, Inc

    Modesto, California

  • Eye Research Foundation

    Newport Beach, California

  • Retina Consultants of San Diego

    Poway, California

  • Retinal Consultants Medical Group

    Sacramento, California

  • Bay Area Retina Associates - Walnut Creek

    Walnut Creek, California

  • Colorado Retina Associates

    Lakewood, Colorado

  • Connecticut Eye Consultants, PC

    Danbury, Connecticut

  • Retina Group of New England, PC

    Waterford, Connecticut

  • Rand Eye Institute

    Deerfield Beach, Florida

  • Retina Group of Florida

    Fort Lauderdale, Florida

  • Eye Associates of Pinellas

    Pinellas Park, Florida

  • Retina Vitreous Associates of Florida

    St. Petersburg, Florida

  • Southeast Retina Center, PC

    Augusta, Georgia

  • University Retina and Macula Associates

    Lemont, Illinois

  • Illinois Retina Associates - Oak Park

    Oak Park, Illinois

  • Butchertown Clinical Trials

    Louisville, Kentucky

  • Mid Atlantic Retina Specialists

    Hagerstown, Maryland

  • Ophthalmic Consultants of Boston

    Boston, Massachusetts

  • Retina Consultants of Minnesota

    Edina, Minnesota

  • Mississippi Retina Associates

    Madison, Mississippi

  • University of Missouri Health System

    Columbia, Missouri

  • Envision Ocular, LLC

    Bloomfield, New Jersey

  • Eye Associates of New Mexico

    Albuquerque, New Mexico

  • Long Island Vitreoretinal Consultants - Westbury

    Westbury, New York

  • Verum Research, LLC

    Eugene, Oregon

  • Mid Atlantic Retina - Bethlehem

    Bethlehem, Pennsylvania

  • Charleston Neuroscience Institute - Charleston

    Charleston, South Carolina

  • Tennessee Retina

    Nashville, Tennessee

  • Austin Clinical Research, LLC

    Austin, Texas

  • Retina Consultants of Texas - Beaumont

    Beaumont, Texas

  • Retina Consultants of Texas-Bellaire-67493

    Bellaire, Texas

  • Retina Foundation of the Southwest

    Dallas, Texas

  • Retina Consultants of Texas - Katy

    Katy, Texas

  • Red River Research Partners, LLC

    Plano, Texas

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.